Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen

Jade Ghosn, Giampiero Carosi, Santiago Moreno, Vadim Pokrovsky, Adriano Lazzarin, Gilles Pialoux, Jose Sanz-Moreno, Agnes Balogh, Eric Vandeloise, Sophie Biguenet, Ghislaine Leleu, Jean Francois Delfraissy

Research output: Contribution to journalArticle

Abstract

Background: Triple combination therapy based on a ritonavir (RTV)-boosted protease inhibitor plus two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) has improved outcomes in HIV type-1 (HIV-1)-infected patients. For patients unable to tolerate these regimens, alternative therapeutic approaches are needed. Methods: We report a comparative, open-label study in treatment-naive patients who underwent initial induction treatment with a triple combination including RTV-boosted atazanavir (ATV; 300/100 mg once daily). Patients who achieved an HIV-1 viral load + T-cell counts were also similar between the treatment arms. Although both regimens were well-tolerated, unboosted ATV was associated with fewer adverse events, fewer total bilirubin abnormalities and an improved lipid profile compared with ATV/RTV. Conclusions: An HIV-1 combined treatment regimen based on unboosted ATV is a feasible treatment option for patients with established virological control who are unable to tolerate triple combination therapy including ATV/RTV.

Original languageEnglish
Pages (from-to)993-1002
Number of pages10
JournalAntiviral Therapy
Volume15
Issue number7
DOIs
Publication statusPublished - 2010

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Ghosn, J., Carosi, G., Moreno, S., Pokrovsky, V., Lazzarin, A., Pialoux, G., Sanz-Moreno, J., Balogh, A., Vandeloise, E., Biguenet, S., Leleu, G., & Delfraissy, J. F. (2010). Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen. Antiviral Therapy, 15(7), 993-1002. https://doi.org/10.3851/IMP1666